Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12Breast 8Genitourinary 7Sarcoma 6Gastrointestinal 4Other solid neoplasm 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Advanced Refractory Solid Tumors 2

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Radiation Dose Hypofractionation × Other solid neoplasm × Clear all
NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
66 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡